Up to 89% of AML cases, and up to 81% of acute lymphoblastic leukemia (ALL) cases, express CDX2 [93,94,95,96] and at least for ALL, CDX2 expression levels were directly associated with the aggressiveness of the disease [93,95]. This evidence concerns the gene CDX2 and acute myeloid leukemia.